NasdaqCM:OPRX

Stock Analysis Report

Executive Summary

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has OptimizeRx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.06%

OPRX

0.9%

US Healthcare Services

-0.2%

US Market


1 Year Return

-5.6%

OPRX

8.7%

US Healthcare Services

1.1%

US Market

OPRX underperformed the Healthcare Services industry which returned 8.7% over the past year.

OPRX underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

OPRXIndustryMarket
7 Day-0.06%0.9%-0.2%
30 Day0.3%-5.2%2.5%
90 Day4.0%-5.5%1.6%
1 Year-5.6%-5.6%8.8%8.7%3.4%1.1%
3 Year383.0%383.0%49.7%49.4%45.2%35.8%
5 Year334.7%334.7%50.3%49.4%62.6%44.8%

Price Volatility Vs. Market

How volatile is OptimizeRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is OptimizeRx undervalued based on future cash flows and its price relative to the stock market?

338.37x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

OptimizeRx's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

OptimizeRx's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

OptimizeRx is overvalued based on earnings compared to the US Healthcare Services industry average.

OptimizeRx is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

OptimizeRx is poor value based on expected growth next year.


Price Based on Value of Assets

OptimizeRx is overvalued based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is OptimizeRx expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

76.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

OptimizeRx's revenue is expected to grow significantly at over 20% yearly.

OptimizeRx's earnings are expected to grow significantly at over 20% yearly.

OptimizeRx's revenue growth is expected to exceed the United States of America market average.

OptimizeRx's earnings growth is expected to exceed the United States of America market average.

OptimizeRx's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if OptimizeRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has OptimizeRx performed over the past 5 years?

10.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

OptimizeRx's year on year earnings growth rate has been positive over the past 5 years.

OptimizeRx has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

OptimizeRx has become profitable in the last year making it difficult to compare the US Healthcare Services industry average.


Return on Equity

OptimizeRx has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

OptimizeRx used its assets less efficiently than the US Healthcare Services industry average last year based on Return on Assets.


Return on Capital Employed

OptimizeRx has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is OptimizeRx's financial position?


Financial Position Analysis

OptimizeRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

OptimizeRx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

OptimizeRx has no debt.

OptimizeRx currently has no debt however we can't compare to 5 years ago as we have no data for that period.

OptimizeRx has no debt, it does not need to be covered by operating cash flow.

OptimizeRx has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

OptimizeRx has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is OptimizeRx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate OptimizeRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate OptimizeRx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as OptimizeRx has not reported any payouts.

Unable to verify if OptimizeRx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as OptimizeRx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of OptimizeRx's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Will Febbo (50yo)

3.6yrs

Tenure

US$923,138

Compensation

Mr. William J. Febbo, also known as Will, has been the Chief Executive Officer and Director of OptimizeRx Corp since February 22, 2016. Mr. Febbo is a Founder of Plexuus, an early stage payment processing  ...


CEO Compensation Analysis

Will's remuneration is about average for companies of similar size in United States of America.

Will's compensation has increased in line with OptimizeRx recently becoming profitable.


Management Age and Tenure

3.1yrs

Average Tenure

54yo

Average Age

The tenure for the OptimizeRx management team is about average.


Board Age and Tenure

2.3yrs

Average Tenure

62.5yo

Average Age

The average tenure for the OptimizeRx board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$81,76407 Jun 19
Wolverine Asset Management, LLC
EntityCompany
Shares5,310
Max PriceUS$16.05
BuyUS$92,63807 Jun 19
Wolverine Asset Management, LLC
EntityCompany
Shares6,577
Max PriceUS$14.85
SellUS$583,21922 May 19
AWM Investment Company Inc.
EntityCompany
Shares42,874
Max PriceUS$13.63
SellUS$1,120,22413 May 19
AWM Investment Company Inc.
EntityCompany
Shares82,126
Max PriceUS$13.76
SellUS$322,10819 Mar 19
AWM Investment Company Inc.
EntityCompany
Shares21,397
Max PriceUS$15.15
BuyUS$9,99820 Dec 18
Miriam Paramore
EntityIndividual
Role
President
President
Shares1,015
Max PriceUS$9.85
BuyUS$19,88020 Dec 18
William Febbo
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares2,000
Max PriceUS$9.94
BuyUS$9,79208 Nov 18
William Febbo
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares600
Max PriceUS$16.32

Ownership Breakdown


Management Team

  • Will Febbo (50yo)

    CEO & Director

    • Tenure: 3.6yrs
    • Compensation: US$923.14k
  • Doug Baker (62yo)

    Chief Financial Officer

    • Tenure: 5.3yrs
    • Compensation: US$425.70k
  • Miriam Paramore (56yo)

    President

    • Tenure: 2.1yrs
    • Compensation: US$445.28k
  • Terry Hamilton (54yo)

    Senior Vice President of Sales

    • Tenure: 3.7yrs
    • Compensation: US$511.63k
  • James Brooks (50yo)

    Consultant

    • Tenure: 2.7yrs
    • Compensation: US$420.99k
  • Steve Silvestro

    Chief Commercial Officer

    • Tenure: 0.4yrs

Board Members

  • Pat Spangler (63yo)

    Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$105.78k
  • Will Febbo (50yo)

    CEO & Director

    • Tenure: 3.6yrs
    • Compensation: US$923.14k
  • Gus Halas (68yo)

    Chairman

    • Tenure: 2.3yrs
    • Compensation: US$130.90k
  • Lynn Vos (63yo)

    Independent Director

    • Tenure: 4yrs
    • Compensation: US$103.15k
  • Jay Pinney (62yo)

    Head of Medical Advisory Board

    • Tenure: 1.5yrs
    • Compensation: US$112.91k
  • Jim Lang (54yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$120.28k

Company Information

OptimizeRx Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OptimizeRx Corporation
  • Ticker: OPRX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$221.250m
  • Shares outstanding: 14.14m
  • Website: https://www.optimizerx.com

Number of Employees


Location

  • OptimizeRx Corporation
  • 400 Water Street
  • Suite 200
  • Rochester
  • Michigan
  • 48307
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OPRXNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDJun 2005

Biography

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to med ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:59
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.